Table 1 Patient characteristics
n | Entire Cohort | Neo-Adjuvant Chemoradiation group | ||||
|---|---|---|---|---|---|---|
AC | SCC | p | AC | SCC | p | |
36 | 143 | 14 | 70 | |||
Age in y; median (range) | 48 (27–82) | 51 (24–89) | 0.196 | 47.5 (38–65) | 57 (24–89) | 0.070 |
Follow-up in m; median (range) | 54 (7–138) | 50 (3–148) | 0.218 | 59 (7–135) | 36 (7–133) | 0.033 |
Tumor FIGO stage, n (%) | ||||||
 IA | 1 (3) | 1 (1) | 0.862 | 0 | 0 |  |
 IA1 | 0 (0) | 5 (3) | 0.567 | 0 | 0 |  |
 IA2 | 0 (0) | 8 (6) | 0.317 | 0 | 0 |  |
 IB | 2 (6) | 2 (1) | 0.380 | 0 | 0 |  |
 IB1 | 18 (50) | 36 (25) | 0.007 | 1 (7) | 1 (1) | 0.749 |
 IB2 | 2 (6) | 11 (8) | 0.934 | 2 (14) | 6 (9) | 0.868 |
 IIA | 0 (0) | 2 (1) | 1 | 0 | 0 |  |
 IIA1 | 0 (0) | 1 (1) | 1 | 0 | 0 |  |
 IIA2 | 2 (6) | 1 (1) | 0.193 | 1 (7) | 0 | 0.368 |
 IIB | 9 (25) | 49 (34) | 0.388 | 8 (57) | 43 (61) | 1 |
 IIIA | 0 (0) | 8 (6) | 0.317 | 0 | 6 (9) | 0.570 |
 IIIB | 2 (6) | 12 (8) | 0.826 | 2 (14) | 8 (11) | 1 |
 IVA | 0 (0) | 7 (5) | 0.382 | 0 | 6 (9) | 0.570 |
Tumor TNM stage, n (%) | ||||||
 I | 21 (58) | 52 (36) | 0.027 | 2 (14) | 2 (3) | 0.251 |
 II | 8 (22) | 33 (23) | 1 | 7 (50) | 27 (39) | 0.619 |
 III | 7 (19) | 50 (35) | 0.113 | 5 (36) | 34 (49) | 0.557 |
 IV | 0 (0) | 8 (6) | 0.317 | 0 (0) | 7 (10) | 0.480 |
Pelvic lymph node status, n (%) | ||||||
 negative | 26 (72) | 83 (58) | 0.172 | 11 (79) | 34 (49) | 0.078 |
 positive | 10 (28) | 55 (38) | 0.319 | 3 (21) | 36 (51) | 0.078 |
 unknown, n (%) | 0 (0) | 5 (3) | 0.567 | 0 (0) | 0 (0) | 1 |
Tumor size, cm | ||||||
 median (range) | 3.5 (0.4–7.0) | 4.3 (0.1–10.5) | 0.028 | 4.3 (2.3–7) | 5.5 (1.8–8.2) | 0.056 |
 unknown, n (%) | 2 (6) | 24 (17) | 0.149 | 0 | 2 (3) | 1 |
Depth invasion, cm | ||||||
 median (range) | 1 (0.3–1.7) | 0.8 (0.1–5) | 0.905 | – | – |  |
 primary surgery, n (%) | 13 (36) | 46 (32) | 0.801 | – | – |  |
 unknown, n (%) | 9 (25) | 14 (10) | 0.031 | – | – |  |
 no primary surgery, n (%) | 14 (39) | 83 (58) | 0.061 | – | – |  |
Chemotherapy concomitant, n (%) | ||||||
 yes | – | – |  | 13 (93) | 62 (89) | 1 |
 no | – | – |  | 1 (7) | 8 (11) | 1 |
Differentiation status, n (%) | ||||||
 well | 11 (31) | 9 (6) | 0.0001 | 3 (21) | 2 (3) | 0.039 |
 moderate | 9 (25) | 68 (48) | 0.024 | 3 (21) | 32 (46) | 0.166 |
 poor | 7 (19) | 43 (30) | 0.288 | 1 (8) | 22 (32) | 0.126 |
 unknown | 9 (25) | 23 (16) | 0.315 | 7 (50) | 14 (20) | 0.043 |
LVSI, n(%) | ||||||
 negative | 7 (19) | 14 (10) | 0.187 | – | – |  |
 positive | 11 (31) | 32 (22) | 0.419 | – | – |  |
 unknown | 4 (11) | 14 (10) | 1 | – | – |  |
 no primary surgery | 14 (39) | 83 (58) | 0.061 | – | – |  |
Patient outcome, n (%) | ||||||
 alive/censored | 33 (92) | 107 (75) | 0.0498 | 13 (93) | 46 (66) | 0.088 |
 disease-specific death | 2 (6) | 20 (14) | 0.274 | 0 | 15 (21) | 0.126 |
 other cause of death | 0 (0) | 14 (10) | 0.107 | 0 | 8 (11) | 0.406 |
 unknown | 1 (3) | 2 (1) | 1 | 1 (7) | 1 (1) | 0.749 |